Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement
about
sameAs
The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceHigh-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisTicagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateEffects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrelStent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapyPlatelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Percutaneous coronary intervention: recommendations for good practice and training.Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery diseaseClinical importance of aspirin and clopidogrel resistanceIncreased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).Antiplatelet resistance and the role of associated variables in stable patients treated with stenting.Very Late Stent Thrombosis due to Neointimal Rupture After Paclitaxel-Eluting Stent ImplantationCytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.Aspirin prophylaxis for the prevention of thrombosis: expectations and limitationsBoth PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary interventionTicagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation.Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12)Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention.The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stentingClinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastographyAspirin and clopidogrel response variability: review of the published literatureComparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.Influence of genetic variations on levels of inflammatory markers of healthy subjects at baseline and one week after clopidogrel therapy; results of a preliminary studyCYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsEvaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adultsLow-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial.Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention.Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonistCYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.
P2860
Q24794673-97D146ED-E21D-4311-800B-1B93C0784733Q26771106-1D4DF62C-B3F6-4310-B91E-F82AD375B5F3Q26801867-C6B5F876-1B7F-4B7B-B736-20DC0CF57584Q26824850-E01999A5-E546-44EF-9BE5-78E0AB42E746Q26996325-18AA2797-8003-47B9-9C56-7DD5FBD042FAQ27006031-51E5ACD4-A5D9-49DE-8DF0-097F075EA190Q28214082-E181B11D-E02B-466B-9CC6-C628E6F98ABDQ28218066-FD82067C-CC30-4DA6-9C54-DF69263E1F7BQ28219354-57368B7E-1832-4DEB-B42C-0D329147B785Q30479477-681B7531-101A-470E-A849-6E340303657AQ33569289-DE1573FE-1C74-4030-B684-6BCC6384F87FQ33902628-CE4D606A-66DA-4D27-A5E7-D2DCFB69B10AQ34019342-EC44017F-FFDF-460F-8298-8DFFAB4C424EQ34352152-B073046F-AF2A-4042-8EF6-1559A93D7455Q34390050-AD7A085D-A47C-42A8-B014-4BA709CAA391Q34568130-0F73DC80-11D1-4352-826D-07F5FEF22FDFQ35208684-019D6AD7-B4F6-4152-925E-BF5BAA51A843Q35214494-C5490EBC-CCA4-49A6-944D-68B82B5E15D3Q35670509-A1DF8989-BBC5-44EF-9F00-4EA34D1CC991Q35683705-22D3F7B3-86FE-4E7B-B0C3-B7EE9AE633A9Q35788838-EB14A3BD-52AE-4F9C-97A1-C95DCD0208DFQ35959359-C3E85FCE-BC9B-45ED-9789-0BD90149341BQ36039469-B5224903-E5EC-4139-861E-3511E79958B1Q36131394-911E24B5-A0EC-450C-AE29-8409D9A0E214Q36174036-3AFF15D2-F34F-4E77-A507-514A5DFEF388Q36216896-637BF8AB-21CC-449D-8AC1-E3E3BA31AC8BQ36620421-B43020F5-2ADF-40AE-A010-3850E9CCEA03Q36800844-FE152731-DE6E-4A2F-A28B-A47D9BFB26ACQ36932221-7FE2FA15-79C6-4174-B4F7-4077CE35EE51Q36976793-A8C28841-0AE5-43D2-B2EA-90ED78D67766Q37139179-9E3F783F-2A5B-4FEF-A36A-CEC1DA932368Q37140633-4816BCA9-260B-4969-BE4A-5EFE19442E77Q37167282-E9407C9C-57CA-4261-AA5B-53C851434255Q37198888-E0B0030C-2E32-4213-B7CE-1C1B29A69E73Q37268748-3228A183-E0D9-44DD-B143-F2E442BDD397Q37388236-A9C11EA0-C483-47DA-80F5-4759FB863F04Q37458916-DEFCB8A9-CF7A-4685-A902-5B73D9634EC2Q37498604-CB6B0427-A22B-4600-A2EE-2740AA38DF5EQ37552005-7195E3FF-7131-498D-8FDE-B1F7EEFEAA4FQ37624492-B6C4D498-A196-46EA-96C4-5876E0F1A2D8
P2860
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@ast
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@en
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@nl
type
label
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@ast
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@en
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@nl
prefLabel
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@ast
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@en
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@nl
P2093
P3181
P1476
Prevalence of clopidogrel non- ...... ctive coronary stent placement
@en
P2093
Albert Schönig
Christian Schulz
Felicitas Besta
Iris Müller
Meinrad Gawaz
Steffen Massberg
P304
P3181
P407
P577
2003-05-01T00:00:00Z